FDA Drug Shortage: Diltiazem Hydrochloride Injection (To Be Discontinued)

Lead

FDA has designated Diltiazem Hydrochloride Injection as "To Be Discontinued," signaling a planned permanent market withdrawal by the sole remaining manufacturer. This status triggers supply chain obligations under FDA's drug shortage reporting requirements and forces wholesale distributors to manage allocation, communicate with downstream buyers, and prepare for complete inventory depletion with no resupply.

Background

FDA maintains a public drug shortage database under authority granted by the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 and expanded by the FDA Reauthorization Act (FDARA) of 2017. Under 21 U.S.C. § 356c, manufacturers must notify FDA at least six months before discontinuing a "medically necessary" drug. FDA designates shortage status in three tiers: "Currently in Shortage" (supply cannot meet demand), "Resolved" (supply restored), and "To Be Discontinued" (manufacturer plans permanent withdrawal).

Wholesale drug distributors operate under FDA registration requirements (21 U.S.C. § 360) and state licensure. While distributors are not required to file discontinuation notices themselves, they inherit supply chain obligations when a product reaches "To Be Discontinued" status: managing remaining inventory, documenting allocation decisions for audit defense, and notifying trading partners of imminent unavailability.

Key Details

Product: Diltiazem Hydrochloride Injection, 25mg/5mL and 50mg/10mL vials

Manufacturer: Fresenius Kabi USA (sole remaining supplier)

FDA Shortage Status: To Be Discontinued (as of posting date on FDA Drug Shortages Database)

Estimated Discontinuation Date: Not publicly disclosed by Fresenius Kabi or FDA

Therapeutic Use: Intravenous calcium channel blocker for acute atrial fibrillation/flutter rate control and supraventricular tachycardia

No alternative diltiazem IV formulation is currently marketed in the U.S. Hospital formularies are being advised to transition to alternative rate-control agents (metoprolol injection, esmolol infusion) where clinically appropriate. FDA has not issued an enforcement discretion policy allowing temporary importation or compounding beyond existing 503A/503B regulations.

Impact Assessment

Wholesale distributors holding diltiazem injection inventory face three immediate compliance considerations:

Allocation and Distribution of Equity: Under state anti-hoarding statutes (e.g., California Business and Professions Code § 4169) and general commercial reasonableness standards, distributors must document allocation criteria if demand exceeds remaining supply. Priority allocation to existing hospital contracts over spot purchasers is defensible, but distributors cannot selectively withhold inventory to drive price increases. Compliance teams should retain allocation decision logs for potential state board of pharmacy inquiries.

Expiration Date Management: Remaining diltiazem injection stock will approach expiration without replenishment. Distributors must implement enhanced short-dated inventory flagging to prevent dispensing expired product. State boards require distributors to quarantine and properly dispose of expired controlled substances and prescription drugs under 21 CFR 1307.21 and state-specific pharmacy law.

Trading Partner Communication: DSCSA requires wholesale distributors to maintain transaction documentation (transaction history, transaction information, transaction statement) for all prescription drug transfers. When a distributor's last available unit ships, documented communication to downstream buyers regarding product unavailability protects against breach-of-contract claims and supports regulatory defense in audits. Distributors should retain copies of shortage notifications sent to hospital and retail pharmacy accounts.

Cold Chain Considerations: Diltiazem injection requires storage at controlled room temperature (20-25°C, excursions permitted 15-30°C per USP <659>). While not a refrigerated product, distributors managing allocation must ensure remaining inventory has not been exposed to temperature excursions during the shortage period. Any compromise of storage conditions must be documented and reported under state pedigree requirements.

This discontinuation represents a category-level supply failure — the only FDA-approved IV formulation of a guideline-recommended acute rate-control agent. Distributors cannot substitute oral diltiazem or other dosage forms without prescriber authorization under state pharmacy substitution laws.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions, of which 1,234 (97%) hold active FDA establishment registration — the baseline requirement for handling prescription drugs like diltiazem injection. However, only 63 entities (5%) hold NABP Accreditation, indicating a minority of distributors have undergone the enhanced quality systems audit that specifically evaluates shortage management protocols and allocation documentation practices.

The average compliance score across tracked entities is 51/100, placing the industry median in the "Fair" tier. This score reflects verification of basic regulatory requirements (state licensure, FDA registration) but limited visibility into operational quality systems. For distributors managing a drug shortage with allocation and expiration date pressures, operational compliance becomes critical — areas where self-reported data from unaccredited entities provides less assurance than NABP-verified systems.

73 entities in the ColdChainCheck directory have at least one FDA recall on record. While not directly related to shortage management, recall history signals potential weaknesses in inventory control, expiration date monitoring, and documentation practices — the same capabilities required to manage diltiazem injection allocation without regulatory exposure.

Practical Guidance for Compliance Officers

• Verify your distributor's FDA registration status: Use the ColdChainCheck directory to confirm active FDA establishment registration for any distributor supplying diltiazem injection or substitutes. "To Be Discontinued" products increase audit scrutiny — state boards expect distributors to handle allocation professionally. Unregistered or suspended entities carry higher regulatory risk during high-visibility shortages.

• Check NABP Accreditation for allocation assurance: If your organization sources from multiple distributors during a shortage, prioritize NABP-accredited entities for critical product allocation. Accreditation verifies documented policies for equitable distribution during shortages — a key audit defense point. Filter the directory by "NABP Accredited: Yes" to identify these 63 entities.

• Document your trading partner due diligence: State pharmacy boards expect specialty pharmacies and hospitals to verify distributor credentials before purchasing shortage products. Download compliance score reports from ColdChainCheck to document that you checked licensure, registration, and enforcement history before accepting diltiazem injection from a secondary source.

• Monitor for recall and warning letter activity: Entities scrambling to manage shortage allocation may cut corners on storage conditions or documentation. Set up tracking for any distributors in your supply chain with prior recalls (73 entities flagged in ColdChainCheck). A second recall during a shortage period signals systemic quality failure.

ColdChainCheck continuously updates compliance scores and regulatory signals as new FDA, state board, and NABP data becomes available. For ongoing shortage monitoring and DSCSA compliance guidance, see the wholesale distributor compliance guide.

Disclaimer: This article provides informational content based on publicly available FDA data and regulatory statutes. It is not legal or compliance advice. Entities should verify all regulatory requirements with FDA, state boards of pharmacy, and qualified legal counsel before making operational decisions.